Larimar Therapeutics
LRMR
5 hedge funds and large institutions have $28.6M invested in Larimar Therapeutics in 2014 Q2 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$13.2M |
| 2 |
VM
VHCP Management
New York
|
+$10.7M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.75M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$693K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$313K |
Top Sellers
LRMR Hedge Fund Activity: Q2 2014 in Review
5 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q2 2014, worth a combined $28.6M.
Buyers outnumbered sellers: 5 funds opened new LRMR positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Bain Capital Public Equity Management, opening a new position worth an estimated $13.2M.
- 5 institutional investors held Larimar Therapeutics (LRMR) as of Q2 2014, up from 0 in Q1 2014.
- Funds reported $28.6M of Larimar Therapeutics stock for Q2 2014.
- 5 funds opened new Larimar Therapeutics positions in Q2 2014 and 0 closed out, a net change of +5 holders.
- The largest Larimar Therapeutics buyer in Q2 2014 was Bain Capital Public Equity Management, an estimated $13.2M added.
Based on aggregated 13F filings for Q2 2014.